Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE W DEXTROMETHORPHAN versus ZYRTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE W DEXTROMETHORPHAN versus ZYRTEC.
PROMETHAZINE W/ DEXTROMETHORPHAN vs ZYRTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist and antiemetic; dextromethorphan is a non-opioid antitussive that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
5 mL (containing promethazine 6.25 mg and dextromethorphan 15 mg) orally every 4-6 hours as needed, not to exceed 30 mL (promethazine 37.5 mg, dextromethorphan 90 mg) per 24 hours.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Promethazine: 9-16 h; dextromethorphan: 3-5 h (extensive metabolizers), 30-50 h (poor metabolizers). Clinical context: dosing interval typically 4-6 h for dextromethorphan; promethazine accumulates with repeated dosing.
Terminal elimination half-life is approximately 8-11 hours in healthy adults, prolonged in renal impairment (e.g., up to 20 hours in moderate renal failure).
Renal: promethazine ~6% unchanged, dextromethorphan ~0.5% unchanged; metabolites primarily renal. Biliary/fecal: minor routes for both.
Cetirizine is primarily excreted unchanged in urine (approximately 70% renal elimination) and feces (about 10%).
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine